Skip to content
  • Home
  • About
    • Team
      • Our Board
      • Management Team
      • Clinical Ambassadors
    • Corporate Governance
    • Our Name & Brandmark
  • Care Delivery
    • Pax Centre
    • Emerald Clinics
    • Maritime Health Clinic
  • Drug and Therapy Development
    • Psychedelic-Assisted Therapy
    • Ultra-Pure CBD Medicines
    • MDMA-inspired Medicines
    • Research & Data Programs
  • Investor Hub
    • Shareholder Communications
  • News
    • General News
    • Blogs
    • Publications
    • Investor Updates
    • In the Media
  • Contact
Menu
  • Home
  • About
    • Team
      • Our Board
      • Management Team
      • Clinical Ambassadors
    • Corporate Governance
    • Our Name & Brandmark
  • Care Delivery
    • Pax Centre
    • Emerald Clinics
    • Maritime Health Clinic
  • Drug and Therapy Development
    • Psychedelic-Assisted Therapy
    • Ultra-Pure CBD Medicines
    • MDMA-inspired Medicines
    • Research & Data Programs
  • Investor Hub
    • Shareholder Communications
  • News
    • General News
    • Blogs
    • Publications
    • Investor Updates
    • In the Media
  • Contact

We Are

A clinical biotech creating tomorrow’s therapies from today’s patient stories.

Our latest Development Programs

News & Events

Get up to speed with our latest news.

  • November 23, 2023

Proactive Interview

  • November 21, 2023

New Independent Non-Executive Chairman

  • June 14, 2023

“MDMA & Modern Medicine” Podcast with Psychiatrist Dr Ben Sessa

  • May 31, 2023

Psychedelic Therapy Training Begins with Dr Ben Sessa

  • May 10, 2023

Study finds Medicinal Cannabis May Have Impact on Quality of Life

  • April 24, 2023

Emyria Unveils Highest Potency CBD Capsule for FDA Pathway

  • April 17, 2023

Emyria to Develop Psilocybin Therapy Care Model

  • April 3, 2023

Aspen Australia & Emyria Agreement for EMD-RX5

  • March 22, 2023

Strong Recruitment for EMD-RX5 Phase 3 Trial

  • March 19, 2023

MDMA Analogue Library Expands to Address Mental Health Disorders

Drug Development

ULTRA - PURE CANNABINOIDS
Powered By Real World Evidence
Novel Formulation
Medical Indication
Dose Optimisation
Safety Trials
Pivotal Trials
Approval
EMD-RX5
Over the Counter
Psychological Distress
EMD-RX5
Over the Counter
Irritable Bowel Syndrome
EMD-RX7
Prescription
Multiple Medical Conditions
EMD-RX9
Prescription
Multiple Medical Conditions

New Drug Discovery

MDMA - LIKE MEDICINE PROGRAMS
Ongoing Library Expansion
Program
Medical Indication
Discovery
Pre-Clinical
Phase 1
Pivotal Trials
Approval
Program 01
HIGHER POTENCY MDMA
e.g. Drug-assisted psychotherapy
Program 02
SELECTED BRAIN TARGETS
e.g. Parkinson's
Program 03
SELECTED NON-BRAIN TARGETS
e.g. Fibrotic Disease

Innovation

Technology
Description
Concept
Design
Submission
Approval
Launch
OPENLY
REMOTE HEALTH TRACKER
Vital Signs Tracked Via Smartphone CameraCLASS 2A MEDICAL DEVICE

Pax Centre

Aspen

PsychoGenics

UWA

NIH

Palantir

Institute for Respiratory Health

For Investors

Ours is a collaborative vision and venture. We’re bringing people and partners together for the greater good: patients, clinicians, researchers, medical innovators and, of course, investors.

Go to our investor centre
0
%
FDA approvals where real-world evidence (RWE) was provided, and growing.
0
+
Unique data points collected per patient.
$
0
T USD
Trillion USD cost of chronic disease and mental health per year in the US.
DRUG & THERAPY DEVELOPMENT
  • Psychedelic-Assisted Therapy
  • Ultra-Pure CBD Medicines
  • MDMA-inspired Medicines
  • Research & Data Programs
  • Psychedelic-Assisted Therapy
  • Ultra-Pure CBD Medicines
  • MDMA-inspired Medicines
  • Research & Data Programs
CARE DELIVERY
  • Pax Centre
  • Emerald Clinics
  • Maritime Health Clinic
  • Pax Centre
  • Emerald Clinics
  • Maritime Health Clinic
FOR INVESTORS
  • Investor Hub
  • Corporate Governance
  • Investor Hub
  • Corporate Governance
RECENT TWEETS
© 2023 Emyria Limited

Website by Glide

  • Terms
  • Privacy Policy
  • Terms
  • Privacy Policy

Phone
08 6559 2800

Email
info@emyria.com

Linkedin Twitter Youtube